- In March 2023, Pfizer announced a Phase 2 trial for its anti-inflammatory agent aimed at reducing cerebral edema post-hematoma.
- In July 2022, Roche collaborated with a European neurology institute to co-develop biomarkers for drug responsiveness in intracranial hematoma patients.
- In 2024, South Korea’s health authority approved a novel neuroprotective formulation for acute hematoma management in emergency care units.
- The report also highlights emerging trends such as biomarker-driven drug targeting, AI in neuroimaging-based treatment stratification, and integration of neurorehabilitation with pharmacologic therapy.
